A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour

Shandong Suncadia Medicine

Status and phase: Enrolling; Phase 2

Conditions: Advanced Malignant Tumour

Treatments: Drug: HRS-7058 +SHR-9839(sc)+SHR-1316; Drug: HRS-7058 + SHR-1826; Drug: HRS-7058 + Cetuximab; Drug: HRS-7058 + SHR-1826 + SHR-1316; Drug: HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy; Drug: HRS-7058 +SHR-A2102 +BP102; Drug: HRS-7058 +SHR-A2102 +SHR-1316 +BP102; Drug: HRS-7058 + BP102; Drug: HRS-7058 + SHR-9839; Drug: HRS-7058 + SHR-A1202; Drug: HRS-7058 + SHR-1316; Drug: HRS-7058 +SHR-A2102 +SHR-1316; Drug: HRS-7058 +SHR-1316 +BP102

Study type: Interventional

Funder types: Industry

Identifiers

NCT06915142

HRS-7058-201

Details and patient eligibility

About

This study is a multicentre, open phase II clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in combination with antitumor drugs in subjects with advanced malignant tumour. To evaluate the safety, tolerability and efficacy of HRS-7058 in combination with antitumor drugs.

Enrollment: 300 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. The subjects gave informed consent to the study before participating in, and voluntarily signed informed consent;
2. 18 to 75 years old (including both ends), gender is not limited;
3. Subjects with unresectable locally advanced or metastatic solid tumour confirmed by histopathology;
4. Having at least one evaluable or measurable lesion according to the solid tumour response Evaluation Criteria (RECIST 1.1);
5. ECOG Performance Status of 0 or 1;
6. The expected survival time is more than 12 weeks;
7. Be able to ingest drugs and be able to comply with trial and follow-up procedures;
8. Adequate bone marrow and organ function;
9. Female subjects of childbearing potential must undergo a serum pregnancy test within 7 days before the first administration of the study drug, and the result must be negative; and they must not be lactating. Female subjects of childbearing potential and male subjects whose partners are females of childbearing potential must agree to comply with contraceptive requirements from the time of signing the informed consent form until 5 months after the last administration of the study drug (for male subjects) or 8 months after the last administration of the study drug (for female subjects).

Exclusion criteria

1. Accompanied by untreated or active central nervous system (CNS) tumour metastasis;
2. Antitumor therapy within 28 days prior to initial use of the investigational drug;
3. The adverse reactions of previous anti-tumour therapy have not recovered to CTCAE ≤ grade 1;
4. With known or suspected interstitial pneumonia;
5. With severe cardiovascular and cerebrovascular disease
6. Had other malignancies within five years prior to first use of the investigational drug;
7. Severe infection within 28 days prior to first use of the investigational drug;
8. History of immune deficiency;
9. Refractory nausea, vomiting, or other gastrointestinal disorders that affect the use of oral medications;
10. The presence of uncontrolled pleural, abdominal or pericardial effusion;
11. Had undergone major organ surgery within 28 days prior to the first use of the study drug;
12. Women during pregnancy or lactation;
13. Known allergies and contraindications to the investigational drug or any of its components;
14. According to the judgment of the investigator, there are any other circumstances that may increase the risks of participating in the study, interfere with the study results, or make the subjects unsuitable for participating in this study.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

300 participants in 13 patient groups

HRS-7058 + SHR-1316

Experimental group

Treatment:

Drug: HRS-7058 + SHR-1316

HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy

Experimental group

Treatment:

Drug: HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy

HRS-7058 + Cetuximab

Experimental group

Treatment:

Drug: HRS-7058 + Cetuximab

HRS-7058 + SHR-1826

Experimental group

Treatment:

Drug: HRS-7058 + SHR-1826

HRS-7058 + SHR-1826 + SHR-1316

Experimental group

Treatment:

Drug: HRS-7058 + SHR-1826 + SHR-1316

HRS-7058 + SHR-A1202

Experimental group

Treatment:

Drug: HRS-7058 + SHR-A1202

HRS-7058 + BP102

Experimental group

Treatment:

Drug: HRS-7058 + BP102

HRS-7058 + SHR-9839

Experimental group

Treatment:

Drug: HRS-7058 + SHR-9839

HRS-7058 +SHR-A2102 +SHR-1316

Experimental group

Treatment:

Drug: HRS-7058 +SHR-A2102 +SHR-1316

HRS-7058 +SHR-9839(sc)+SHR-1316

Experimental group

Treatment:

Drug: HRS-7058 +SHR-9839(sc)+SHR-1316

HRS-7058 +SHR-1316 +BP102

Experimental group

Treatment:

Drug: HRS-7058 +SHR-1316 +BP102

HRS-7058 +SHR-A2102 +BP102

Experimental group

Treatment:

Drug: HRS-7058 +SHR-A2102 +BP102

HRS-7058 +SHR-A2102 +SHR-1316 +BP102

Experimental group

Treatment:

Drug: HRS-7058 +SHR-A2102 +SHR-1316 +BP102